Bharat Biotech gets DCGI nod for PHASE II trials of COVAXIN

The subject expert committee (SEC) has recommended that the trial will be conducted on 380 participants
Read Article

According to a report by The Indian Express, the Drugs Controller General of India (DCGI) has given clearance to Bharat Biotech for conducting Phase II human clinical trials of its indigenously developed Covaxin.

The report informed that the subject expert committee (SEC) has recommended that the trial will be conducted on 380 participants. A letter from Joint Drugs Controller Dr S Eswara Reddy, dated September 3, has notified the company about this.

Reportedly, the first phase of the Covaxin trial was done with 375 participants from across 12 sites.

Zydus Cadila and Serum Institute of India have also started conducting phase II trials for ZyCoV-D and Covishield (by Oxford-AstraZeneca) in India.

Bharat BiotechClinical TrialsCOVAXINCovid 19 vaccineDCGIPhase II trials
Comments (3)
Add Comment
  • Yash Pal

    Phase 2 trial should have been started by or about 15 Aug. In this emergency situation also, it is take it easy policy

  • k.k.chatterjee

    success of united opposition to stall progress at any cost.

  • Maninder Singh

    When all vaccine maker starts phase 1 & phase 2 simultaneously why BB vaccine delayed it when india is suffering most ?